Dr. Reddy's Laboratories Limited

DRREDDY

INE089A01023

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:58 2024-07-05 EDT			5-day change	1st Jan Change
6,523 ^INR	+0.62%		+4.54%	+12.50%

05:14pm	Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	MT
07-03	Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT

Sub: Audio Recordings of the Investor call conducted on June 26, 2024 Form 6 K

June 28, 2024 at 06:17 am

Sub: Audio Recordings of the Investor call conducted on June 26, 2024

Please find below the link of the audio recordings of the Investor call, conducted on June 26, 2024.

Weblink: https://www.drreddys.com/cms/cms/sites/default/files/2024-06/Investor%20Call%20Stock%20Exchange%20Intimation%20-%20Nicotinell%20Acquisition%20Jun%202024.mp3

This is for your information and records.

Thanking you.

Yours faithfully,

For Dr. Reddy's Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer, and Head-CSR

Attachments

Original Link
Permalink

Disclaimer

Dr. Reddy's Laboratories Limited published this content on 28 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 June 2024 10:15:56 UTC.

Latest news about Dr. Reddy's Laboratories Limited

Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	11:14am	MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	07-03	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note	07-01	MT
Dr. Reddy's to Co-market Zydus' Breast Cancer Treatment in India	06-28	MT
Zydus and Dr. Reddy's Announces Licensing Agreement for Co-Marketing of Pertuzumab Biosimilar, a Critical Treatment for Breast Cancer Patients in India	06-28	CI
India plans incentives for diabetes, obesity drug makers in 2026, government official says	06-28	RE
Indian Equities Fall on Friday, Dragged Mainly by Banking Stocks	06-28	MT
Asian Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	06-27	MT
Dr. Reddy's to Acquire Haleon's Nicotine Replacement Therapy Business Outside US	06-27	MT
INDIA STOCKS-UltraTech Cement, Reliance power Indian shares to record highs	06-27	RE
Dr. Reddy's Laboratories to Acquire Nicotinell Portfolio From Haleon	06-26	MT
Haleon to Sell Nicotine-Quitting Aid Business for $634 Million -- Update	06-26	DJ
Transcript : Dr. Reddy's Laboratories Limited - Special Call	06-26
Haleon to Sell Nicotine-Quitting Aid Business for $634 Million	06-26	DJ
Haleon to sell nicotine replacement therapy business outside US for $633 mln	06-26	RE
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading	06-25	MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	06-24	MT
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	06-21	MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	06-18	MT
Indian Equities Close at Record Highs on Tuesdays, Led by Realty, Private Bank Stocks	06-18	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading	06-17	MT
Asian Equities Traded in the US as American Depositary Receipts Drop Sharply in Thursday Trading	06-13	MT
Dr. Reddy's Laboratories Limited Receives an Order from the Joint Commissioner of State Tax,, Raipur Division-1, Chattisgarh	06-13	CI
Asian Equities Traded in the US as American Depositary Receipts Surge Higher in Wednesday Trading	06-12	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	06-10	MT

Chart Dr. Reddy's Laboratories Limited

Duration

Period

More charts

Company Profile

Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows: - sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines; - sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services; - other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc. Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).

Sector

Pharmaceuticals

Calendar

2024-07-15 - Détachement de for final dividend

Related indices

NIFTY 50 , NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Dr. Reddy's Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

6,523 INR

Average target price

6,161 INR

Spread / Average Target

-5.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DR. REDDY'S LABORATORIES LIMITED	+12.50%	12.93B
ELI LILLY AND COMPANY	+56.89%	809B
NOVO NORDISK A/S	+39.52%	624B
JOHNSON & JOHNSON	-6.55%	351B
ABBVIE INC.	+7.92%	289B
ASTRAZENECA PLC	+13.74%	240B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	166B
PFIZER, INC.	-2.57%	157B

Other Pharmaceuticals

Dr. Reddy's Laboratories Limited

Equities

DRREDDY

INE089A01023

Pharmaceuticals

Sub: Audio Recordings of the Investor call conducted on June 26, 2024 Form 6 K

EPS Revisions